

From CERN technologies to Medical Applications



Photo: CERN




Photo: MARS Bioimaging



Knowledge Transfer
Accelerating Innovation

Manuela Cirilli,
Medical Applications Advisor
CERN Knowledge Transfer group

CERN's technological innovations have applications in many fields

CERN is the birthplace of the World Wide Web

And there are many more examples
Medical imaging, cancer therapy, material science, cultural heritage, aerospace, automotive, environment, health & safety, industrial processes.



Radioprotection 2005
Vol. 40, n° 2, pages 245 à 255


DOI: 10.1051/radiopro:2005010

Produit nouveau

Une nouvelle imagerie ostéo-articulaire basse dose en position debout : le système EOS

J. DUBOUSSET¹, G. CHARPAK², I. DORION², W. SKALLI³, F. LAVASTE³,
J. DEGUISE⁴, G. KALIFA⁵, S. FERREY⁵

Georges Charpak, Fabio Sauli and
Jean-Claude Santiard working on a
multiwire chamber in 1970




First mouse imaged at CERN with Na-¹⁸F in 1978

David Townsend and Alan Jeavons

SCAN OF MOUSE SKELETON . 5.7 μ Ci, F¹⁸ (positron emission)
 1 bin \equiv 1mm x 1mm. Plane spacing = 1 cm.

TOMOGRAM

RECONSTRUCTION




+ 8.0 cm.




+ 9.0 cm.



+ 10.0 cm.





Phys. Med. Biol., 1983, Vol. 28, No. 9, 1009–1019. Printed in Great Britain
A general method for three-dimensional filter computation


B Schorr†, D Townsend‡ and R Clack‡

† DD Division, CERN, Geneva, Switzerland

‡ Department of Nuclear Medicine, Cantonal Hospital, Geneva, Switzerland


Received 24 September 1982, in final form 7 February 1983

Abstract. Application of the Fourier space deconvolution algorithm to three-dimensional (3D) reconstruction problems necessitates the computation of a frequency space filter; which requires taking the 3D Fourier transform of the system response function. In this paper, it is shown that for system response functions of the specific form $d(\theta, \varphi)/r^2$, with $d(\theta, \varphi)$ an angular function describing the imaging system, the filter computation can always be reduced to a single integration which, in many cases, may be performed analytically. Complete expressions are derived for the general 3D filter, and two examples are given to illustrate the use of such expressions.






1980s: Marilena Streit-Bianchi and the CERN Radiobiology group



Apparatus for growing broad beans which have been exposed to radiation. The roots are immersed in a tank of running water (CERN 439.10.80). Right: Chromosomal aberration (A) in a dividing cell (B) of *Vicia Faba* exposed to a 250 GeV hadron beam.



A gauche, dispositif de culture des fèves irradiées. Les racines plongent dans un bac d'eau courante (photo CERN 439.10.80). A droite, aberrations chromosomiques (A) parmi une cellule en division (B) de *Vicia Faba* exposée à un faisceau de hadrons de 250 GeV.

Beans in Beams

The CERN Radiobiology Group carries out experiments to study the effects of radiation on living cells. The purpose of the research is to compare the effects of different kinds of radiation, to ascertain how far these effects are modified by variations in dosage and application (i.e. one or several sessions) and to examine the repair mechanisms of cells following exposure to radiation. Tests were carried out on human blood, mice and broad beans. As the absorption of radiation causes the same types of damage for all cells, a relatively simple detector was chosen for a recent experiment — the broad bean, which is easy to handle. Its root-tip (or meristem) is composed of cells which are particularly sensitive to radiation, thus enabling rapid analysis of the damage to be made. Two kinds of investigation were carried out on the beans: physiological investigation to ascertain the reduction in the rate of growth of the roots after exposure to radiation, and microscopic investigation to ascertain the damage to the cells and chromosomes. In this way it has proved possible to study the effects of neutrons produced at the 600 MeV SC at doses as low as 200 millirads. The results obtained indicate that at the lower end of the range studied damage increases linearly with dose for both neutrons and gamma radiation. This is of considerable importance for our understanding of the effects of radiations are in progress. Broad beans have also been used to study the biological effects of 250 GeV hadrons supplied by the SPS.

Des fèves dans le faisceau?

Le groupe de Radiobiologie du CERN se livre à une série d'expériences qui étudient les effets des radiations sur les cellules vivantes. Le but de ces recherches est de comparer les effets produits par divers types de rayonnements, d'étudier la variation des effets en fonction de la dose et de son mode d'administration (séance unique ou fractionnée) ainsi que les mécanismes de réparations cellulaires après irradiation. Plusieurs détecteurs biologiques sont employés : sang humain, souris, fèves. Etant donné que l'absorption des radiations cause le même type de dégâts dans toutes les cellules, on a choisi pour une expérience récente un détecteur relativement simple comme la fève qui est très facile à manipuler. L'extrémité de sa racine (ou méristème) est formée de cellules particulièrement sensibles aux radiations et permettant une analyse rapide des dégâts produits. Des recherches de deux types ont été effectuées avec les fèves : l'une (physiologique) est de déterminer la réduction de la croissance des racines après irradiation; l'autre (microscopique) consiste à évaluer les dégâts produits au niveau des cellules et des chromosomes. C'est ainsi qu'on a pu étudier les effets de neutrons produits par le synchro-cyclotron de 600 MeV à des doses aussi faibles que 200 millirads. Les résultats obtenus indiquent que les dégâts augmentent de façon linéaire avec la dose, à la limite inférieure de la gamme étudiée, aussi bien pour les neutrons que pour les rayons gamma. Cela est d'un grand intérêt et permet de mieux comprendre les effets des radiations. L'étude des effets de neutrons à des énergies plus faibles est en cours. Les fèves ont aussi permis d'étudier les effets biologiques produits par des hadrons de 250 GeV fournis par le SPS.

Strategy and framework approved by CERN Council in 2017

CERN/SPC/1091/RA
CERN/FC/6125/RA
CERN/3311/RA
Original: English
23 May 2017

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE
CERN EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

Action to be taken

Voting Procedure

For information	SCIENTIFIC POLICY COMMITTEE 304 th Meeting 12 & 13 June 2017	
For information	FINANCE COMMITTEE 360 th Meeting 13 & 14 June 2017	
For approval	RESTRICTED COUNCIL 185 th Session 16 March 2017	Simple majority of Member States represented and voting

**Strategy and framework applicable to knowledge transfer
by CERN for the benefit of medical applications**

The Council is invited to approve the strategy and framework set out in this document for medical applications-related activities, and to take note of the information contained in [Annexes I and II](#).

Updated strategy paper

Approved by CERN Council in June

<https://cds.cern.ch/record/2864317?ln=en>

CERN/SPC/1091/Rev.
CERN/FC/6125/Rev.
CERN/3311/Rev.
Original: English
6 June 2023

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE
CERN EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

Action to be taken

Voting Procedure

For information	SCIENTIFIC POLICY COMMITTEE 334 th Meeting 19-20 June 2023	-
For information	FINANCE COMMITTEE 386 th Meeting 20-21 June 2023	-
For decision	RESTRICTED COUNCIL 212 th Session 22-23 June 2023	Simple majority of Member States represented and voting

Updated strategy and framework applicable to knowledge transfer by CERN for the benefit of medical applications

The Council is invited to take note of the information set out in this document and to approve the updated strategy and framework for medical-applications-related projects set out therein.

ICT for medical applications

Nuclear Medicine

Medical Imaging

Radiotherapy

Radiation Monitoring and Dosimetry

Robotics

Medical devices

Over 70 companies and institutes produce accelerators for industrial applications; these organizations sell more than **1,100 industrial systems per year** — almost twice the number produced for research or medical therapy — at a **market value of \$2.2B.**

Over **\$1B** of this amount is generated by the sales of accelerators for **ion implantation** into materials — primarily semiconductor devices — whose worldwide value of production is about \$300B.


Hamm, R. and Hamm, M. (2012). Industrial accelerators and their applications. World Scientific Publishing Co.


As of 2014 there were **42,200** accelerators worldwide:
27,000 (64%) in industry,
14,000 (33%) for medical purposes
1,200 (3%) for basic research.

These figures exclude electron microscopes and x-ray tubes, and the security and defense industries.

Chernyaev, A. P. and Varzar, S. M. (2014). Particle accelerators in modern world. *Physics of Atomic Nuclei*, 77(10):1203–1215.

Area	Application	Beam	Accelerator	Beam energy/MeV	Beam current/ mA	Number
Medical	Cancer therapy	e	linac	4-20	10^{-2}	>14000
		p	cyclotron, synchrotron	250	10^{-6}	60
		C	synchrotron	4800	10^{-7}	10
	Radioisotope production	p	cyclotron	8-100	1	1600
Industrial	Ion implantation	B, As, P	electrostatic	< 1	2	>11000
	Ion beam analysis	p, He	electrostatic	<5	10^{-4}	300
	Material processing	e	electrostatic, linac, Rhodatron	≤ 10	150	7500
	Sterilisation	e	electrostatic, linac, Rhodatron	≤ 10	10	3000
Security	X-ray screening of cargo	e	linac	4-10	?	100?
	Hydrodynamic testing	e	linear induction	10-20	1000	5
Synchrotron light sources	Biology, medicine, materials science	e	synchrotron, linac	500-10000		70
Neutron scattering	Materials science	p	cyclotron, synchrotron, linac	600-1000	2	4
Energy - fusion	Neutral ion beam heating	d	electrostatic	1	50	10
	Heavy ion inertial fusion	Pb, Cs	Induction linac	8	1000	Under development
	Materials studies	d	linac	40	125	Under development
Energy - fission	Waste burner	p	linac	600-1000	10	Under development
	Thorium fuel amplifier	p	linac	600-1000	10	Under development
Energy - bio-fuel	Bio-fuel production	e	electrostatic	5	10	Under development
Environmental	Water treatment	e	electrostatic	5	10	5
	Flue gas treatment	e	electrostatic	0.7	50	Under development





Courtesy Maurizio Vretenar

Status of Radiation Therapy Equipment

155 **7602**

Countries


RT Centres

14875

MV Therapy



Equipment type

(Updated on : 23/06/2021 09:19:53)



Equipment per income groups

(Updated on : 23/06/2021 09:19:53)




IAEA


DIRAC

Directory of
Manual
Radiotherapy centres

Protons, ions: hadron therapy, particle therapy, (light, heavy) ion therapy



X-rays




Relative dose




depth

Carbon ion beams



Relative dose



depth

<https://doi.org/10.1186/1878-5085-4-9>

Status of Radiation Therapy Equipment

20 **106**

Countries RT Centres

110

Light Ion Therapy

Equipment type

(Updated on : 23/06/2021 09:19:53)

MV Therapy 14,875

Brachytherapy 3,318

Light Ion Therapy 110


Equipment per income groups

(Updated on : 23/06/2021 09:19:53)


High income (H) 99

Upper middle income (UM) 10

Lower middle income (LM) 1



From the PIMMS Study @



EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH
CERN - PS DIVISION

CERN/PS 2000-007 (DR)

PROTON-ION MEDICAL MACHINE STUDY (PIMMS) PART II

Accelerator Complex Study Group*
supported by the Med-AUSTRON, Onkologie-2000 and the TERA Foundation
and hosted by CERN

ABSTRACT

The Proton-Ion Medical Machine Study (PIMMS) group was formed following an agreement between the Med-AUSTRON (Austria) and the TERA Foundation (Italy) to combine their efforts in the design of a cancer therapy synchrotron capable of accelerating either light ions or protons. CERN agreed to support and host this study in its PS Division. A close collaboration was also set up with GSI (Germany). The study group was later joined by Onkologie-2000 (Czech Republic). Effort was first focused on the theoretical understanding of slow extraction and the techniques required to produce a smooth beam spill for the conformal treatment of complex-shaped tumours with a sub-millimetre accuracy by active scanning with proton and carbon ion beams. Considerations for passive beam spreading were also included for protons. The study has been written in two parts. The more general and theoretical aspects are recorded in Part I and the specific technical design considerations are presented in the present volume, Part II. An accompanying CD-ROM contains supporting publications made by the team and data files for calculations. The PIMMS team started its work in January 1996 in the PS Division and continued for a period of four years.

*Full-time members: L. Badano¹⁾, M. Benedikt²⁾, P.J. Bryant²⁾ (Study Leader), M. Crescenti¹⁾, P. Holy³⁾, A. Maier²⁾⁴⁾, M. Pullia¹⁾, S. Reimoser²⁾⁴⁾, S. Rossi¹⁾,
Part-time members: G. Borri¹⁾, P. Knaus¹⁾²⁾
Contributors: F. Gramatica¹⁾, M. Pavlovic¹⁾, L. Weisser⁵⁾
1) TERA Foundation, via Puccini, 11, I-28100 Novara.
2) CERN, CH 1211 Geneva-23.
3) Oncology-2000 Foundation, Na Morani 4, CZ-12808 Prague 2.
4) Med-AUSTRON, c/o RIZ, Prof. Dr. Stephan Korenstr.10, A-2700 Wr. Neustadt.
5) Sommer & Partner Architects Berlin (SPB), Hardenbergplatz 2, D-10623 Berlin.

Geneva, Switzerland
May 2000

PIMMS


August 2000



fondazione CNAO



MedAustron



Sources
to generate

1 RF cavity
to accelerate

16 Dipoles
to bend

20 Correctors
to steer


Linac
to pre-
accelerate

24 Quadrupoles
to focus

From pioneering rasterscanning & carbon ion pilot project @



440 patients
1998-2008




The image shows an optimized plan with two opposite fields for a chordoma patient using protons (left) or ^{12}C ions (right).



Since 2009*:
2841 patients with p
3793 patients with C-ion

* Until Dec 2020, source ptcog.ch

200



Multi heavy ions
(protons +
carbon ions)

2






proton multi-room



proton single-
room


Courtesy
(I'll never thank him enough!)
Marco Durante (GSI)
JENAS 2019

Protons: the LINAC way

1990 RFQ2 200 MHz 0.5 MeV /m Weight :1200kg/m Ext. diametre : ~45 cm	2007 LINAC4 RFQ 352 MHz 1MeV/m Weight : 400kg/m Ext. diametre : 29 cm	2014 HF RFQ 750MHz 2.5MeV/m Weight : 100 kg/m Ext. diametre : 13 cm
		

Compact High-Frequency Radio Frequency Quadrupole (RFQ)

M. Vretenar, A. Dallochio, V. A. Dimov, M. Garlasché, A. Grudiev, A. M. Lombardi, S. Mathot, E. Montesinos, M. Timmins, "A Compact High-Frequency RFQ for Medical Applications", in Proc. LINAC2014, Geneva, Switzerland, September 2014



Licensed to AVO-ADAM

Next Ion Medical Machine Study (NIMMS)



Why ions?

Proton therapy is now commercially available.

Ion therapy (mainly carbon) still bespoke facilities.


An R&D programme based at CERN for critical technologies related to ion therapy

Focus on the development of key technologies (a toolbox) corresponding to CERN core competences.

Three alternative accelerator designs


Improved synchrotron (warm)

Equipped with several innovative features: multi-turn injection for higher beam intensity, new injector at higher gradient and energy, multiple extraction schemes, multi-ion. Circumference ~ 75 m



Improved synchrotron (superconducting)

Equipped with the same innovative features as warm, but additionally 90° superconducting magnets. Circumference ~ 27 m





Courtesy: TERA





Linear accelerator

Linear sequence of accelerating cells, high pulse frequency. Length ~ 53 m




Other options considered as less interesting because of cost and/or required R&D: RC synchrotron, FFAG, SC cyclotron, PWFA

The RFQ for C⁶⁺ LINAC option




First (of 4 sections) completed




Collaboration CERN-CIEMAT-CDTI-Spanish industry
2.0 m long
750 MHz
Will deliver Carbon (or Helium) at 5 MeV (total energy)
Designed at CERN built in Spanish Industry

R&D on gantries

GaToroid: A Novel Concept for a Superconducting Compact and Lightweight Gantry for Hadron Therapy



Collaboration CNAO-INFN-CERN-MedAustron
start 2022



EuroSIG



70 ANNI DI RICERCA DISEGNANDO IL FUTURO
1951 2021 infn

Superconducting Ion Gantry

CSN5 – Call 2021
SIG
Superconducting Ion Gantry

Lucio Rossi
Università di Milano e sezione INFN di Milano – LASA
R. Musenich INFN-GE, L. Sabbatini INFN-S, S. Giordanengo e E. Fiorina INFN-TO



FLASH therapy – a growing clinical interest

NATURE

May 23, 1959 VOL. 183

Modification of the Oxygen Effect when Bacteria are given Large Pulses of Radiation

D. L. DEWEY
J. W. BOAG

Research Unit in Radiobiology,
British Empire Cancer Campaign,
Mount Vernon Hospital,
Northwood.

> [Sci Transl Med.](#) 2014 Jul 16;6(245):245ra93. doi: 10.1126/scitranslmed.3008973.

Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice

Vincent Favaudon¹, Laura Caplier², Virginie Monceau³, Frédéric Pouzoulet⁴, Mano Sayarath⁴, Charles Fouillade⁴, Marie-France Poupon⁴, Isabel Brito⁵, Philippe Hupé⁶, Jean Bourhis⁷, Janet Hall⁴, Jean-Jacques Fontaine², Marie-Catherine Vozenin⁸

Affiliations + expand

PMID: 25031268 DOI: [10.1126/scitranslmed.3008973](#)

In vitro studies suggested that sub-millisecond pulses of radiation elicit less genomic instability than continuous, protracted irradiation at the same total dose. To determine the potential of ultrahigh dose-rate irradiation in radiotherapy, we investigated lung fibrogenesis in C57BL/6J mice exposed either to short pulses (≤ 500 ms) of radiation delivered at ultrahigh dose rate (≥ 40 Gy/s, FLASH) or to conventional dose-rate irradiation (≤ 0.03 Gy/s, CONV) in single doses. The growth of human HBCx-12A and HEP-2 tumor xenografts in nude mice and syngeneic TC-1 Luc(+) orthotopic lung tumors in C57BL/6J mice was monitored under similar radiation conditions. CONV (15 Gy) triggered lung fibrosis associated with activation of the TGF- β (transforming growth factor- β) cascade, whereas no complications developed after doses of FLASH below 20 Gy for more than 36 weeks after irradiation. FLASH irradiation also spared normal smooth muscle and epithelial cells from acute radiation-induced apoptosis, which could be reinduced by administration of systemic TNF- α (tumor necrosis factor- α) before irradiation. In contrast, FLASH was as efficient as CONV in the repression of tumor growth. Together, these results suggest that FLASH radiotherapy might allow complete eradication of lung tumors and reduce the occurrence and severity of early and late complications affecting normal tissue.

FLASH therapy – a growing clinical interest



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com




Original Article

Treatment of a first patient with FLASH-radiotherapy

Jean Bourhis^{a,b,*}, Wendy Jeanneret Sozzi^a, Patrik Gonçalves Jorge^{a,b,c}, Olivier Gaide^d, Claude Bailat^c, Frédéric Duclos^a, David Patin^a, Mahmut Ozsahin^a, François Bochud^c, Jean-François Germond^c, Raphaël Moeckli^{c,1}, Marie-Catherine Vozenin^{a,b,1}

^a Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; ^b Radiation Oncology Laboratory, Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; ^c Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne; and ^d Department of Dermatology, Lausanne University Hospital and University of Lausanne, Switzerland



Vozenin et al
Clin Cancer Res
2018




Fig. 1. Temporal evolution of the treated lesion: (a) before treatment; the limits of the PTV are delineated in black; (b) at 3 weeks, at the peak of skin reactions (grade 1 epithelitis NCI-CTCAE v 5.0); (c) at 5 months.


First human patient – skin cancer treated with 10 MeV-range electrons

FLASH VHEE therapy

CLIC technology for a FLASH VHEE facility being developed in collaboration with CHUV (Lausanne University Hospital) and THERYQ (ALCEN Group)



Close-up of the Compact Linear Collider prototype, on which the electron FLASH design is based (Image: CERN)



An intense beam of electrons is produced in a photoinjector, accelerated to around 100 MeV and then is expanded, shaped and guided to the patient.

The design of this facility is the result of an intense dialogue between groups at CHUV and CERN.

Jean Bourhis from CHUV:
“The clinical need that we have really converges with the technological answer that CERN has.”

The remarkable connection between CLIC technology and FLASH electron therapy

Very intense electron beams

CLIC – to provide brightness needed for delicate physics experiments

FLASH – to provide dose fast for biological FLASH effect

Very precisely controlled electron beams

CLIC – to reduce the power consumption of the facility

FLASH – to provide reliable treatment in a clinical setting

High accelerating gradient (that is high beam energy gain per length)

CLIC – fit facility in Lac Lemman region and limit cost


FLASH – fit facility on typical hospital campuses and limit cost of treatment



CERN KT Seminar on April 26th, 2021
<https://indico.cern.ch/event/975980/>

The CERN Linear Electron Accelerator for Research (CLEAR)

CLEAR is a versatile 200 MeV electron linac + a 20m experimental beamline, operated at CERN as a multi-purpose user facility.




VHEE activities in CLEAR

Calibration of operational medical dosimeters
– nonlinear effects with high-dose short pulses


Verification of FLASH effect using biological dosimeters

Experimental verification of dose deposition profiles in water phantoms

Demonstration of “Bragg-like peak” deposition with focused beams




Films set-up for profile depth dose, CHUV Lausanne (M.C. Vozenin, C. Bailat, R. Moeckli et al.)



Advance Markus chambers and SRS Array, Oldenburg University and PTW (B. Poppe, D. Poppinga et al.)



Calorimeter and ROOS chamber, Nat. Phys. Lab. UK (A. Subiel et al.)



Strathclyde and Manchester

A. Lagdza, R. Jones et al., Influence of heterogeneous media on Very High Energy Electron (VHEE) dose penetration and a Monte Carlo-based comparison with existing radiotherapy modalities, Nuclear Inst. and Meth. in Physics Research, B, 482 (2020) 70-81.

M. McManus, A. Subiel et al., The challenge of ionisation chamber dosimetry in ultra-short pulsed high dose-rate Very High Energy Electron beams, Nature Scientific Reports (2020) 10-9089.


Small, K.L., Henthorn, et al., Evaluating very high energy electron RBE from nanodosimetric pBR322 plasmid DNA damage, Nature Sci. Rep. 11, 3341 (2021).

D. Poppinga et al., VHEE beam dosimetry at CERN Linear Electron Accelerator for Research under ultra-high dose rate conditions, 2021 Biomed. Phys. Eng. Express 7 015012.

Kokurewicz, K., Brunetti, E., Curcio, A. et al. An experimental study of focused very high energy electron beams for radiotherapy, Nature Commun. Phys. 4, 33 (2021).

Medipix


A family of pixel detector read-out chips for particle imaging and detection developed by the Medipix Collaborations



A photograph of a Medipix1 chip, showing a dense array of colorful pixels (red, green, blue, purple) on a dark substrate, mounted on a circuit board.

Medipix1 Collaboration

The Medipix1 collaboration was formed in the 1990's when the potential of the new technology to provide noise-free single-photon counting was demonstrated.



A photograph of a Medipix2 probe card, showing a square chip with a colorful pixel array mounted on a green PCB. Various components like capacitors (C10, C11, C12, C13, C14, C15, C16) and integrated circuits (IC1, IC2) are visible.

Medipix2 Collaboration


The Medipix2 Collaboration was formed in 1999 with the aim of developing a single photon counting pixel detector readout chip using a 0.25 μm CMOS process.



A photograph of a Medipix3 chip, showing a square, light-colored pixel array mounted on a dark substrate.

Medipix3 Collaboration

The Medipix3 Collaboration was formed in 2005 to develop the Medipix3 chip and the Timepix3 chip: now permitting colour imaging and dead time free operation.






A photograph of two Medipix4 chips, one purple and one red, showing their pixel arrays and circuitry.


Medipix4 Collaboration

The Medipix4 Collaboration was launched in 2017. The aim is designing pixel read-out chips fully prepared for TSV processing that may be tiled on all four sides.

Hybrid Silicon Pixel Detectors





Noise-hit free particle detection
Standard CMOS can be used allowing on-pixel signal processing
Sensor material can be changed (Si, GaAs, CdTe..)




Ethanol-preserved mouse heart scanned using the WidePIX_{10x5} detector
60 kVp tungsten spectrum
720 projections, 5 seconds per projection (one hours total)
Spatial resolution ca. 7 μ m
Reconstructed using Voxel, visualized using CTVox and Amide software

Colour x-ray of a lighter



S. Procz et al.


Spectroscopic information permits material separation



The water has been partly cut away to reveal the bone, gold, gadolinium and iodine


Images presented at the European Congress of Radiology, Vienna, March 2017.

Fast forward to 2018



CT versus MARS

Standard CT




Metal artifact hides the bone-metal interface

Metal artefact

Scaphoid screw

MARS



The bone-metal interface is visualised enabling assessment of peri-implant infection and osteolysis

MARS SPCCT Imaging technology is in concept development for human use. It is not a product and is not cleared or approved by the US FDA or any other regulator for commercial availability outside of New Zealand




Slide courtesy of Anthony Butler, University of Canterbury


Presented at 6th Workshop on Medical Applications of Spectroscopic X-ray Detectors, 29 Aug 2022, CERN

Molecular versus MARS

MARS - intrinsic information



Gout crystal characterisation
(Collab with CHUV)



Carotid plaque with quantitative measurements
of fat, water, calcium, and iron

MARS SPCCT Imaging technology is in concept development for human use. It is not a product and is not cleared or approved by the US FDA or any other regulator for commercial availability outside of New Zealand




Slide courtesy of Anthony Butler, University of Canterbury

Presented at 6th Workshop on Medical Applications of Spectroscopic X-ray Detectors, 29 Aug 2022, CERN




MiniPIX TPX3

Miniaturized spectral camera supporting Si and CdTe sensors




It's really small...




ADVACAM
Imaging the Unseen

Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources


250 – 300 keV




350 – 400 keV



500 – 550 keV



650 – 700 keV




^{131}I 284 keV (7%)

^{131}I 364 keV

^{22}Na 511 keV

^{137}Cs 662 keV



Gamma camera applications: Thyroid diagnostic

Thyroid cancer diagnostics and treatment monitoring:


The second most frequent cancer for women (after breast cancer)

Current imaging methods offer resolution of about 12 mm in 2D

Our technology allows

5 times better resolution and 3D (2.5 mm)

4 times lower dose



TimePIX 3 photon fluence measurement in hospital theatres




Reference person: 1.76 m

Eye lens - 170 cm

Chest - 135 cm

Belt - 96 cm

Knee - 53 cm





Colour maps of the photon fluence measured with a Timepix III in an hospital theatre at four horizontal eights.

Courtesy of M. Nowak

TimePIX 3 photon fluence measurement in hospital theatres


Energy spectra for each height for a given person




Courtesy of M. Nowak

➡ Shift in energy from head to toes = non homogenous exposure

PET










ClearPET

PET for small animals




ClearPEM

Dedicated scanner for breast imaging



EndoTOFPET

Ultrasound endoscopic PET for diagnosis of pancreas & prostate cancer




Current status commercial TOF-PET



TOF PET SIEMENS: BIOGRAPH VISION



3.2mm section crystals
CTR 215ps





Webpage SIEMENS:

https://static.healthcare.siemens.com/siemens_hwem-hwem_sxxa_websites-context-root/wcm/idc/groups/public/@global/@imaging/@molecular/documents/download/mda4/mzmy/~edisp/biograph_vision_technical_flyer-05440720.pdf

[See presentation KT/EP seminar 6 September 2021 from Maurizio Conti](#)

In the CERN Crystal Clear group: <160 ps with DOI



Type of array	Crystals dim. [mm ³]	DOI resolution FWHM [mm]	En. Res. FWHM @ 511 keV [%]	CTR FWHM [ps], central pixels	
				<i>No correction</i>	<i>With DOI correction</i>
DOI	3.1 x 3.1 x 15	3.0 ± 0.1	8.9 ± 0.2	234 ± 2	157 ± 2

DOI information extracted without degradation of timing properties

M. Pizzichemi et al, Phys. Med. Biol. 61 (2016) 4679

Radioisotopes: The medical testing crisis

With a serious shortage of medical isotopes looming, innovative companies are exploring ways to make them without nuclear reactors.

Richard Van Noorden

11 December 2013

PDF Rights & Permissions




Radioisotopes & Nuclear Medicine

Classification of isotopes for Medicine:

- 1. Established isotopes → Industrial suppliers
 ^{99m}Tc , ^{18}F , $^{123,125,131}\text{I}$, ^{111}In , ^{90}Y
- 2. Emerging isotopes → Small innovative suppliers
 ^{68}Ga , ^{82}Rb , ^{89}Zr , ^{177}Lu , ^{188}Re
- 3. R&D isotopes → Research labs
 $^{44,47}\text{Sc}$, $^{64,67}\text{Cu}$, ^{134}Ce , ^{140}Nd , $^{149, 152, 155, 161}\text{Tb}$, ^{166}Ho , ^{195m}Pt , ^{211}At , 212 , ^{213}Bi , ^{223}Ra , ^{225}Ac , ...



Courtesy U. Koester



68Ga-PSMA-11 PET/CT scans of patient B. In comparison to initial tumor spread (A), restaging after 2 cycles of β -emitting $^{177}\text{Lu-PSMA}$ -617 presented progression (B).
Clemens Kratochwil et al. J Nucl Med 2016;57:1941-1944

Theranostics

<p>Tb 149</p> <p>4.2 m 4.1 h</p> <p>ε β⁺ α 3.99 γ 796; 165...</p> <p>ε α 3.97 β⁺ 1.8 γ 352; 165...</p>	<p>Tb 152</p> <p>4.2 m 17.5 h</p> <p>ly 283; 160... ε; β⁺... γ 344; 411...</p> <p>ε β⁺ 2.8... γ 344; 586; 271...</p>
<p>Tb 155</p> <p>5.32 d</p> <p>ε γ 87; 105;... 180, 262</p>	<p>Tb 161</p> <p>6.90 d</p> <p>β⁻ 0.5; 0.6... γ 26; 49; 75... e⁻</p>





A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

Cristina Müller, Konstantin Zhernosekov, Ulli Köster, Karl Johnston, Holger Dorrer, Alexander Hohn, Nico T. van der Walt, Andreas Türler and Roger Schibli



Journal of Nuclear Medicine December 2012, 53 (12) 1951-1959; DOI: <https://doi.org/10.2967/jnumed.112.107540>

ISOLDE has been running @CERN for > 50 years




CERN-MEDICIS

Non-conventional isotopes collected by mass separation for new medical applications



MEDICIS Target Irradiation


“Free” proton beam (otherwise lost in the dump)




Rail Conveyor System



MEDICIS Laboratory






Some MEDICIS isotopes :

High activity Sm-153, Ba/Cs-128, Tm/Er-165

Defined by the MEDICIS CB board,
1st-proof-of-concepts type of studies



From CERN-MEDICIS to the lab/Hospital
(Countries: BE, CH, FR, PK, PT, LV, UK)


PRISMAP – The European medical radionuclides programme



Achievements in 2022:

15 projects for biomedical research with novel radionuclides selected across Europe


www.prismap.eu/access/user-projects (BE, CZ, DE, ES, FR, IT, PT, UK)



PRISMAP invited to present research needs in the field of novel biomedical radionuclides to the EU Commissioner for research and education Mariya Gabriel



New “theranostics” (therapy+diagnostics) radionuclides




Research Topical issue
in Frontiers in Medicine

Cicone F et al: Internal radiation dosimetry of a (^{152}Tb) -labeled antibody in tumor-bearing mice. *EJNMMI Res.* 2019 Jun 11;9(1):53. [doi:10.1186/s13550-019-0524-7](https://doi.org/10.1186/s13550-019-0524-7)

Talip Z., et al;; Production of mass separated erbium-169 towards the first preclinical in vitro investigations. *Frontiers in Medicine* (2021), [doi: 10.3389/fmed.2021.643175](https://doi.org/10.3389/fmed.2021.643175)

Project 12 entitled “*Added Value using Terbium-161 over Lutetium-177 in Combination with the metabolically more stable GRPR Ligand AMTG for Targeted Radiotherapy of GRPR-expressing Malignancies? – A Preclinical Evaluation*” started on 15 November 2022 with the first delivery of Tb-161 by PSI, followed by two additional deliveries in December 2022 by PSI and SCK CEN (<https://www.prismap.eu/news/newsletter-feed/>)



<https://medicis.cern/approved-projects> (32 projects), 23 scientific articles published

Gamma-MRI project

Development of a new medical diagnostic modality

Combine high spatial resolution (MRI) and high sensitivity (radiotracer)

Proof-of-principle by U Virginia: Y. Zheng, et al., Nature 537, 652 (2016)

Polarised gamma-emitting tracer => anisotropic decay

	Detection efficiency	Spatial resolution
PET and SPECT	high	Low (e.g. >5mm for 82Rb)
MRI	low	High

Digital Technologies

```
elif operation == "MIRROR_Y":
    mirror_mod.use_x = False
    mirror_mod.use_y = True
    mirror_mod.use_z = False
elif operation == "MIRROR_Z":
    mirror_mod.use_x = False
    mirror_mod.use_y = False
    mirror_mod.use_z = True

#selection at the end -add back the deselected mirror modifier object
mirror_ob.select= 1
modifier_ob.select=1
bpy.context.scene.objects.active = modifier_ob
print("Selected" + str(modifier_ob)) # modifier ob is the active ob
#mirror_ob.select = 0
#name = bpy.context.selected_objects[0]
#bpy.data.objects[name.name].select = 1
```

Geant4 – a simulation toolkit

Open source

CERN strongly contributes to its core development

Other Geant4 collaboration members developed specific capabilities and applied them in G4 medical applications

Medical Applications

- [G4DNA](#)
Geant4–DNA project
- [G4MED](#) (in Japanese)
Geant4 Medical Physics in Japan
- [G4NAMU](#)
Geant4 North American Medical User Organization
- [GAMOS](#)
Geant4–based Architecture for Medicine–Oriented Simulations
- [GATE](#)
Geant4 Application for Tomographic Emission
- [GHOST](#)
Geant4 Human Oncology Simulation Tool
- [TOPAS](#)
Geant4 Monte Carlo Platform for Medical Applications

GEANT4 collaboration
A SIMULATION TOOLKIT

<http://geant4.cern.ch/>

Geant4: a simulation toolkit
S. Agostinelli *et al.*
NIM A, vol. 506, no. 3, pp. 250-303, 2003

Geant4 Developments and Applications
J. Allison *et al.*
IEEE Trans. Nucl. Sci., vol. 53, no. 1, pp. 270-278, 2006

Recent Developments in Geant4
J. Allison *et al.*
NIM A, vol. 835, pp. 186-225, 2016

Geant4 ASSOCIATES
Experts in Radiation Simulation

Human phantoms






Image of Polygon-Surface Reference Korean Male Phantom (PSRK-Man), implemented in Geant4. Courtesy of C.-H. Kim & C. Choi, Hanyang Univ.


Radiation Environment – model of space station




Courtesy T. Ersmark, KTH Stockholm

Geant4-DNA applications

Simulation using Geant4-DNA of irradiation of a pBR322 plasmid, including radiolysis



- movie courtesy of V. Stepan (NPI-ASCR/CENBG/CNRS/IN2P3/ESA)



Model of nucleosome created using DnaFabric*, imported into Geant4 to model irradiation, repair mechanisms.

* S. Meylan et al, Comp. Phys. Comm. 204 (2016) p159

Tools for specific applications

based on Geant4

Tools provide specific capabilities for creating setups, measuring

create setup, steer simulation via 'text commands'


output adapted for application-area

[GATE](#) (FR, DE, GR, PL, AT) - PET/SPECT,

[TOPAS](#) (US) - protontherapy


[GAMOS](#) (ES) - for nuclear medicine applications

Developed by external parties - using capabilities of G4 toolkit



Example GATE geometries

Triple-head gamma camera



TOPAS Tool for Particle Simulation

To use Monte Carlo transport for radiation therapy research in the past, one had to be both an expert in Monte Carlo and an expert in medical physics. With TOPAS, it is sufficient to be an expert in medical physics or biology


TOPAS has been developed by:
David Hall
Bruce Faddegon
Aimee McNamara
Harald Paganetti
Joseph Perl
Jan Schümann
Jungwook Shin
José Ramos

Thank You NIH !!!!

TOPAS supported by the U.S National Institutes of Health under contracts 2R01CA140735-05 and 1 R01 CA187003-01A1 and by TOPAS MC Inc

A 3D visualization of a proton therapy setup. The detector is shown as a series of stacked layers, colored in green, yellow, and grey. A central region is highlighted in blue and green, representing the patient area. The text 'TOPAS' is at the top left, and 'Tool for Particle Simulation' is at the top right.

Flair – fluka advanced interface



Improvements for medical simulations

Process DICOM standard files for radiotherapy purposes

Provides easy-to use tool for **treatment plan re-simulation** and quantitative comparison

Enables precise description of patient model and beam delivery system

/flɛə(r)/ n [U,C] natural or instinctive ability (to do something well,
to select or recognize what is best, more useful, etc.
[Oxford Advanced Dictionary of Current English]


is more than a graphical Interface

→ is a complete integrated working environment for FLUKA

Greatly enhanced productivity

→ users focus on their problem rather than on technicalities

In this presentation: a selection of results obtained by the CERN group



3D spatial dose distribution simulated with FLUKA


Importing the RT DOSE with the activity mapping of ^{68}Ga

Simulation of the ^{68}Ga decays


Very fast setup time

less than a few minutes with a few clicks from the user

Run FLUKA simulations with no programming skills or file editing requirements!




Sensitivity studies of Monte Carlo TP recalculations



*Proton prostate patient case
(MedAustron)
W.Kozłowska PhD*





CAiMIRA

CERN Airborne Model for Indoor Risk Assessment

Developed by CERN personnel to assess the COVID airborne risk in indoor spaces with a risk-based approach.

Calculator

Simulation name:
Eg. Workshop without masks

Room number:
Eg. TW-033

Virus data:
Variant: SARS-CoV-2 (Omicron VOC)
Vaccinated? No Yes


Room data:
Use data from ARIVE sensors: No Yes
Room volume (m³): Room volume
Floor area (m²): Room floor area
Ceiling height (m): Room ceiling height
Central heating system in use: No Yes
Geographic location: Geneva, CHE

Ventilation data:
Ventilation type: No ventilation Natural
Mechanical HEPA filtration: Yes No

Face masks:
Are masks worn when occupants are at workstations?
 Yes No

Event data:
Total number of occupants: Number
 Deterministic exposure
 Probabilistic exposure (incidence rate)
Number of infected people: 1
Activity type: Office
Exposed person(s) presence: Start: 08:30 Finish: 17:30
Infected person(s) presence: Start: 08:30 Finish: 17:30
Short range interactions (without masks): No Yes
Which month is the event? January
Activity breaks:
 Input separate breaks for infected and exposed person(s)
Lunch break: No Yes
Start: 12:30 Finish: 13:30
Coffee Breaks: No breaks 2 4
Coffee breaks are spread evenly throughout the day.

Generate report



Extension to the medical field of AI tools for

functional and dependency analysis of complex critical infrastructure

digital imaging for radiography autonomous defects detection

Background work:

the CASO platform: AI-assisted diagnosis and predictive maintenance for critical infrastructures operation






the CAFEIN platform: AI-assisted X-ray image analysis for quality control of LHC welds

- **Field of application:**



- Semi-automated analysis and modelling of medical data and images
- Diagnosis and treatments based on multiple features and data beyond human perception
- Federated learning and distributed computing to **ensure privacy** for a wide and safe international **collaboration** as well as access to **diagnostic models in remote areas**

- **Medical application:**

- Brain pathologies detection, analysis and segmentation based on CNN applied to MRI images



Final Output- Screening Tool



MEDICAL APPLICATION
Multi-pathology
detection &
classification

MULTI-INSTITUTIONAL

CERN
CAFEIN

HELLENIC REPUBLIC
National and Kapodistrian
University of Athens
EST. 1837

FAKULTNÍ
NEMOCNICE
BRNO

MARCHESE: Remote Monitoring of Health Parameters

Background: response time of a rescue team of CERN Fire Brigade could take up to 22 minutes in the LHC tunnel.

The research is oriented towards the development of robotic solutions: workers' detection and health contactless monitoring during emergencies situations is important to support in search and rescue scenarios.

PHOTOPLETHYSMOGRAPHY


- Optical technique used to detect volumetric changes in the blood in the peripheral circulation.
- Blood volume changes in microvascular tissue (i.e. at cheeks and forehead level)




Remote PPG: Video pre-processing



30 FPS
 30 images/second
 Logitech 1080p FULL HD
 GPU NVIDIA GTX 1080p




NEURAL NETWORK



SEPARATION of SKIN PIXELS from NO-SKIN PIXELS




REAL TIME



Medical Applications



In contact with Medical Staff in the Hospital

➔ Understand which are the needs of the real scenario



NEWBORN and PATIENTS WITH BURNS

- Fragile skin
- No abrasions and damage of epidermis
- Continuous and constant monitoring



ASSISTIVE ROBOTIC REHABILITATION

- adjust the exercise level (increase or decrease) according to the patient's physiological response
- Exploit residual patient capabilities (assistance-as-needed)



SMART HOSPITAL ROOM

- Hospital room for remote monitoring
 - Avoid medical staff infections
- Hospitalization more comfortable for patients
- Group or single patient monitoring






Photo: CERN



Photo: CNAO treatment room



Knowledge Transfer
Accelerating Innovation

Visit kt.cern